Mycobacterium abscessus SCID Mouse Model for Compound & Vaccine Screening

Unaltered photo by Sarah Fleming

Opportunity

Available for Licensing:

Mycobacterium abscessus SCID Mouse Model for Compound/Vaccine Screening

Inventor

Diane Ordway

Background

Over the last 10 years, Mycobacterium abscessus group strains have emerged as important human pathogens which are associated with significantly higher fatality rate than any other rapidly growing mycobacteria. These opportunistic pathogens are widespread in the environment and can cause a wide range of clinical diseases including skin, soft tissue, central nervous system, and disseminated infections, by far the most difficult to treat is the pulmonary form. Infections with M. abscessus are often multi-drug-resistant (MDR) requiring prolonged treatment with various regimens and many times results in high mortality despite maximal therapy. Over the last 10 years, Mycobacterium abscessus group strains have emerged as important human pathogens which are associated with significantly higher fatality rate than any other rapidly growing mycobacteria. These opportunistic pathogens are widespread in the environment and can cause a wide range of clinical diseases including skin, soft tissue, central nervous system, and disseminated infections, by far the most difficult to treat is the pulmonary form. Infections with M. abscessus are often multi drug-resistant (MDR) requiring prolonged treatment with various regimens and many times results in high mortality despite maximal therapy.

 

 

Licensing Director

Rod Tompkins
Rod.Tompkins@colostate.edu
970-491-7100

Reference No.: 17-026

 

Technology Overview

Researchers at Colorado State University set out to assess the antimycobacterial activity of clarithromycin, clofazimine, bedaquiline, and clofazimine-bedaquiline combinations against M. abscessus in mouse models which fulfilled the criteria of developing high bacterial levels of infection and development of necrotizing granulomas. The group subsequently developed a new preclinical mouse model for antibacterial treatment against Mycobacterium abscessus.

Relevant Publications

Chan, Edward D, et al. “Host Immune Response to Rapidly Growing Mycobacteria, an Emerging Cause of Chronic Lung Disease.” American Journal of Respiratory Cell and Molecular Biology, U.S. National Library of Medicine, Oct. 2010, www.ncbi.nlm.nih.gov/pubmed/20081053.

Obregón-Henao, Andrés, et al. “Susceptibility of Mycobacterium Abscessus to Antimycobacterial Drugs in Preclinical Models.” Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Nov. 2015, www.ncbi.nlm.nih.gov/pubmed/26303795.

Baldwin, Susan L, et al. “The Complexities and Challenges of Preventing and Treating Nontuberculous Mycobacterial Diseases.” PLoS Neglected Tropical Diseases, Public Library of Science, 14 Feb. 2019, www.ncbi.nlm.nih.gov/pubmed/30763316.

Banaschewski, Brandon, et al. “Clofazimine Inhalation Suspension for the Aerosol Treatment of Pulmonary Nontuberculous Mycobacterial Infections.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, U.S. National Library of Medicine, Sept. 2019, www.ncbi.nlm.nih.gov/pubmed/31138497.

Bryant, Josephine M, et al. “Emergence and Spread of a Human-Transmissible Multidrug-Resistant Nontuberculous Mycobacterium.” Science (New York, N.Y.), U.S. National Library of Medicine, 11 Nov. 2016, www.ncbi.nlm.nih.gov/pubmed/27846606.

Verma, et al. “Mycobacterium Avium Infection in a C3HeB/FeJ Mouse Model.” Frontiers, Frontiers, 19 Mar. 2019, www.frontiersin.org/articles/10.3389/fmicb.2019.00693/full.

Orme, Ian M, and Diane J Ordway. “Host Response to Nontuberculous Mycobacterial Infections of Current Clinical Importance.” Infection and Immunity, American Society for Microbiology, Sept. 2014, www.ncbi.nlm.nih.gov/pubmed/24914222.

Hoffner, Sven, and Diane Ordway. “Nontuberculous Mycobacteria (NTM): Ch 4 Future NontuberculousMycobacteria DST AndTherapeutic Interventions.” ScienceDirect, 2019, www.sciencedirect.com/book/9780128146927/nontuberculous-mycobacteria-ntm.

Last updated on October 7, 2019.